Symbols / PLUR Stock $3.37 +0.00% Pluri Inc.

Healthcare • Biotechnology • Israel • NCM
PLUR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Yaacov Yanay
Exch · Country NCM · Israel
Market Cap 36.31M
Enterprise Value 61.72M
Income -26.14M
Sales 1.34M
FCF (ttm) -14.35M
Book/sh -1.46
Cash/sh 1.24
Employees 127
Insider 10d —
IPO Jun 30, 2003
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.77
PEG —
P/S 27.12
P/B -2.30
P/C —
EV/EBITDA -2.53
EV/Sales 46.10
Quick Ratio 0.39
Current Ratio 0.43
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -3.31
EPS next Y -1.90
EPS Growth —
Revenue Growth 7.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-11-12
Earnings (prior) 2025-11-12
ROA -50.60%
ROE —
ROIC —
Gross Margin 40.63%
Oper. Margin -32.86%
Profit Margin 0.00%
Shs Outstand 10.77M
Shs Float 4.53M
Insider Own 40.22%
Instit Own 12.56%
Short Float 0.64%
Short Ratio 4.60
Short Interest 24.13K
52W High 6.10
vs 52W High -44.75%
52W Low 2.82
vs 52W Low 19.50%
Beta 0.72
Impl. Vol. —
Rel Volume 0.02
Avg Volume 7.71K
Volume 167.00
Target (mean) $12.00
Tgt Median $12.00
Tgt Low $12.00
Tgt High $12.00
# Analysts 1
Recom None
Prev Close $3.37
Price $3.37
Change 0.00%
About

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$12.00
Mean price target
2. Current target
$3.37
Latest analyst target
3. DCF / Fair value
$-23.97
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.37
Low
$12.00
High
$12.00
Mean
$12.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-06-02 init Alliance Global Partners — → Buy $12
News
RSS: Latest PLUR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-08 MANIEU ALEXANDRE WEINSTEIN Director and Beneficial Owner of more than 10% of a Class of Security — 625,000 $3.13 $1,956,250
2025-12-04 ABERMAN ZALMAN Director — 346 $0.00 $0
2025-12-04 YANAY YAKY Chief Executive Officer — 6,588 $0.00 $0
2025-12-04 SHEMESH-RASMUSSEN MAITAL Director — 699 $0.00 $0
2025-12-04 LEVI RAMI AVRAHAM Director — 653 $0.00 $0
2025-12-04 MANIEU ALEXANDRE WEINSTEIN Director and Beneficial Owner of more than 10% of a Class of Security — 519 $0.00 $0
2025-12-04 ZALTS LIAT Chief Financial Officer — 3,660 $0.00 $0
2025-12-04 AJCHENBAUM EITAN Director — 668 $0.00 $0
2025-11-12 AJCHENBAUM EITAN Director — 11,685 $0.00 $0
2025-10-29 MANIEU ALEXANDRE WEINSTEIN Director and Beneficial Owner of more than 10% of a Class of Security — 1,002,169 $0.00 $100
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Revenue
1.34
+309.82%
0.33
+13.59%
0.29
+22.65%
0.23
Operating Revenue
1.34
+309.82%
0.33
+13.59%
0.29
+22.65%
0.23
Cost Of Revenue
0.68
+16950.00%
0.00
-55.56%
0.01
0.00
Reconciled Cost Of Revenue
0.68
+16950.00%
0.00
-55.56%
0.01
0.00
Gross Profit
0.65
+103.11%
0.32
+15.83%
0.28
+18.80%
0.23
Operating Expense
22.83
+1.56%
22.48
-18.33%
27.52
-34.20%
41.83
Research And Development
12.85
+3.25%
12.45
-20.95%
15.74
-35.41%
24.38
Selling General And Administration
9.98
-0.55%
10.03
-14.81%
11.78
-32.50%
17.45
General And Administrative Expense
9.98
-0.55%
10.03
-14.81%
11.78
-32.50%
17.45
Other Gand A
9.98
-0.55%
10.03
-14.81%
11.78
-32.50%
17.45
Total Expenses
23.51
+4.57%
22.48
-18.34%
27.53
-34.17%
41.83
Operating Income
-22.18
-0.08%
-22.16
+18.67%
-27.25
+34.49%
-41.59
Total Operating Income As Reported
-22.18
-0.08%
-22.16
+18.67%
-27.25
+34.49%
-41.59
EBITDA
-22.07
-9.10%
-20.23
+26.94%
-27.68
+29.80%
-39.43
Normalized EBITDA
-20.72
-1.06%
-20.50
+20.60%
-25.82
+35.43%
-39.98
Reconciled Depreciation
0.32
+24.90%
0.25
-30.11%
0.36
-65.62%
1.05
EBIT
-22.38
-9.30%
-20.48
+26.98%
-28.04
+30.73%
-40.49
Total Unusual Items
-1.35
-592.70%
0.27
+114.68%
-1.87
-439.27%
0.55
Total Unusual Items Excluding Goodwill
-1.35
-592.70%
0.27
+114.68%
-1.87
-439.27%
0.55
Net Income
-22.58
-8.11%
-20.89
+26.25%
-28.32
+31.33%
-41.24
Pretax Income
-23.25
-8.95%
-21.34
+26.11%
-28.89
+30.18%
-41.37
Net Non Operating Interest Income Expense
0.27
-49.81%
0.54
+140.00%
0.23
+167.98%
-0.33
Interest Expense Non Operating
0.87
+0.81%
0.87
+2.73%
0.84
-4.96%
0.89
Net Interest Income
0.27
-49.81%
0.54
+140.00%
0.23
+167.98%
-0.33
Interest Expense
0.87
+0.81%
0.87
+2.73%
0.84
-4.96%
0.89
Interest Income
1.14
-18.63%
1.41
+29.70%
1.08
+86.57%
0.58
Other Income Expense
-1.35
-592.70%
0.27
+114.68%
-1.87
-439.27%
0.55
Gain On Sale Of Security
-1.35
-592.70%
0.27
+114.68%
-1.87
-439.27%
0.55
Tax Provision
-0.01
0.00
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
-0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-23.25
-8.93%
-21.34
+26.11%
-28.89
+30.18%
-41.37
Net Income From Continuing Operation Net Minority Interest
-22.58
-8.11%
-20.89
+26.25%
-28.32
+31.33%
-41.24
Net Income From Continuing And Discontinued Operation
-22.58
-8.11%
-20.89
+26.25%
-28.32
+31.33%
-41.24
Net Income Continuous Operations
-23.25
-8.93%
-21.34
+26.11%
-28.89
+30.18%
-41.37
Minority Interests
0.67
+46.27%
0.46
-19.43%
0.57
+328.79%
0.13
Normalized Income
-21.23
-0.34%
-21.16
+20.01%
-26.45
+36.70%
-41.79
Net Income Common Stockholders
-22.58
-8.11%
-20.89
+26.25%
-28.32
+31.33%
-41.24
Diluted EPS
-3.56
+10.78%
-3.99
+36.06%
-6.24
+39.06%
-10.24
Basic EPS
-3.56
+10.78%
-3.99
+36.06%
-6.24
+39.06%
-10.24
Basic Average Shares
6.34
+20.93%
5.24
+14.38%
4.58
+13.85%
4.02
Diluted Average Shares
6.34
+20.93%
5.24
+14.38%
4.58
+13.85%
4.02
Diluted NI Availto Com Stockholders
-22.58
-8.11%
-20.89
+26.25%
-28.32
+31.33%
-41.24
Total Other Finance Cost
—
-0.09
-675.00%
0.02
-36.00%
0.03
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Assets
38.68
-2.14%
39.53
-22.19%
50.80
-25.37%
68.06
Current Assets
22.09
-28.97%
31.11
-24.88%
41.41
-28.29%
57.75
Cash Cash Equivalents And Short Term Investments
20.61
-31.26%
29.98
-25.36%
40.17
-26.98%
55.02
Cash And Cash Equivalents
5.89
-13.09%
6.78
+26.55%
5.36
-45.15%
9.77
Other Short Term Investments
14.72
-36.57%
23.20
-33.35%
34.81
-23.06%
45.24
Receivables
0.72
+13.17%
0.64
+21.06%
0.53
-60.11%
1.32
Accounts Receivable
0.42
-15.37%
0.50
+39.17%
0.36
-62.30%
0.95
Other Receivables
0.01
+300.00%
0.00
-94.74%
0.04
+72.73%
0.02
Taxes Receivable
0.29
+114.81%
0.14
+4.65%
0.13
-62.50%
0.34
Prepaid Assets
0.23
+5.86%
0.22
-49.77%
0.44
+9.68%
0.40
Restricted Cash
0.42
+66.14%
0.25
-5.58%
0.27
-73.29%
1.01
Hedging Assets Current
0.10
+1187.50%
0.01
—
0.00
Total Non Current Assets
16.59
+97.01%
8.42
-10.31%
9.39
-9.01%
10.32
Net PPE
8.72
+20.38%
7.25
-12.92%
8.32
-7.64%
9.01
Gross PPE
26.71
+7.07%
24.95
-3.19%
25.77
-1.25%
26.09
Accumulated Depreciation
-17.99
-1.62%
-17.70
-1.45%
-17.45
-2.12%
-17.09
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
2.51
+2.20%
2.46
+3.93%
2.36
+2.78%
2.30
Other Properties
15.03
+9.49%
13.72
-6.25%
14.64
-2.76%
15.05
Leases
9.17
+4.64%
8.77
+0.00%
8.77
+0.29%
8.74
Goodwill And Other Intangible Assets
5.93
0.00
—
—
Goodwill
3.14
0.00
—
—
Other Intangible Assets
2.79
—
—
—
Non Current Prepaid Assets
—
—
—
0.00
Other Non Current Assets
1.33
+88.35%
0.70
+12.10%
0.63
-3.09%
0.65
Total Liabilities Net Minority Interest
39.55
+15.94%
34.11
-3.90%
35.50
-1.06%
35.88
Current Liabilities
32.33
+625.82%
4.45
-20.76%
5.62
-17.69%
6.83
Payables And Accrued Expenses
3.18
+3.62%
3.07
-22.70%
3.97
-13.47%
4.59
Payables
1.42
+3.05%
1.38
-38.98%
2.26
-3.17%
2.33
Accounts Payable
0.87
-10.17%
0.96
-46.80%
1.81
+1.51%
1.78
Other Payable
0.56
+33.73%
0.41
-7.37%
0.45
-18.40%
0.55
Current Accrued Expenses
1.76
+4.08%
1.69
-1.17%
1.71
-24.13%
2.25
Employee Benefits
0.70
+16.20%
0.60
+1.17%
0.60
-31.03%
0.87
Pensionand Other Post Retirement Benefit Plans Current
0.86
+22.36%
0.70
-19.59%
0.87
-17.09%
1.05
Current Debt And Capital Lease Obligation
27.95
+4899.64%
0.56
-10.85%
0.63
+1.29%
0.62
Current Debt
27.29
—
—
—
Other Current Borrowings
27.29
—
—
—
Current Capital Lease Obligation
0.66
+17.89%
0.56
-10.85%
0.63
+1.29%
0.62
Current Deferred Liabilities
0.34
+175.00%
0.12
-17.88%
0.15
+34.82%
0.11
Current Deferred Revenue
0.34
+175.00%
0.12
-17.88%
0.15
+34.82%
0.11
Other Current Liabilities
—
—
—
0.46
Total Non Current Liabilities Net Minority Interest
7.22
-75.66%
29.66
-0.73%
29.88
+2.84%
29.05
Long Term Debt And Capital Lease Obligation
6.10
-79.00%
29.05
-0.77%
29.28
+3.89%
28.18
Long Term Debt
—
24.03
+2.11%
23.53
+8.54%
21.68
Long Term Capital Lease Obligation
6.10
+21.41%
5.03
-12.56%
5.75
-11.64%
6.50
Defined Pension Benefit
0.61
+29.79%
0.47
+7.06%
0.44
-33.59%
0.66
Non Current Pension And Other Postretirement Benefit Plans
0.70
+16.20%
0.60
+1.17%
0.60
-31.03%
0.87
Non Current Deferred Liabilities
0.41
0.00
—
—
Non Current Deferred Taxes Liabilities
0.41
0.00
—
—
Stockholders Equity
-6.84
-7227.08%
0.10
-99.28%
13.36
-55.54%
30.04
Common Stock Equity
-6.84
-7227.08%
0.10
-99.28%
13.36
-55.54%
30.04
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Share Issued
7.89
+45.96%
5.41
+4.90%
5.16
+26.88%
4.06
Ordinary Shares Number
7.89
+45.96%
5.41
+4.90%
5.16
+26.88%
4.06
Additional Paid In Capital
436.21
+3.72%
420.57
+1.85%
412.94
+2.90%
401.30
Retained Earnings
-443.06
-5.37%
-420.47
-5.23%
-399.58
-7.63%
-371.26
Minority Interest
5.98
+12.37%
5.32
+173.47%
1.95
-9.41%
2.15
Total Equity Gross Minority Interest
-0.86
-115.97%
5.42
-64.61%
15.30
-52.46%
32.19
Total Capitalization
-6.84
-128.36%
24.12
-34.60%
36.88
-28.68%
51.72
Working Capital
-10.23
-138.39%
26.65
-25.53%
35.79
-29.71%
50.92
Invested Capital
20.45
-15.24%
24.12
-34.60%
36.88
-28.68%
51.72
Total Debt
34.05
+14.99%
29.61
-0.98%
29.91
+3.83%
28.80
Net Debt
21.39
+24.07%
17.24
-5.10%
18.17
+52.61%
11.91
Capital Lease Obligations
6.76
+21.06%
5.58
-12.39%
6.38
-10.51%
7.12
Net Tangible Assets
-12.77
-13403.13%
0.10
-99.28%
13.36
-55.54%
30.04
Tangible Book Value
-12.77
-13403.13%
0.10
-99.28%
13.36
-55.54%
30.04
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Operating Cash Flow
-18.21
-1.05%
-18.02
+21.16%
-22.86
+37.38%
-36.50
Cash Flow From Continuing Operating Activities
-18.21
-1.05%
-18.02
+21.16%
-22.86
+37.38%
-36.50
Net Income From Continuing Operations
-23.25
-8.93%
-21.34
+26.11%
-28.89
+30.18%
-41.37
Depreciation Amortization Depletion
0.32
+24.90%
0.25
-30.11%
0.36
-65.62%
1.05
Depreciation
0.32
+24.90%
0.25
-30.11%
0.36
-65.62%
1.05
Depreciation And Amortization
0.32
+24.90%
0.25
-30.11%
0.36
-65.62%
1.05
Other Non Cash Items
3.26
+556.34%
0.50
-72.47%
1.80
+181.23%
-2.22
Pension And Employee Benefit Expense
—
—
—
—
Stock Based Compensation
2.14
-18.14%
2.62
-34.17%
3.98
-55.36%
8.91
Operating Gains Losses
-0.56
—
—
—
Gain Loss On Investment Securities
-0.56
—
—
—
Change In Working Capital
-0.13
-180.00%
-0.04
+60.53%
-0.11
+96.02%
-2.87
Change In Receivables
-0.11
-121.60%
0.51
+252.98%
-0.34
-2.13%
-0.33
Changes In Account Receivables
-0.20
-365.79%
0.08
—
—
Change In Prepaid Assets
0.00
+102.27%
-0.04
-105.73%
0.77
+725.81%
0.09
Change In Payables And Accrued Expense
0.10
+109.18%
-1.09
+13.91%
-1.26
+73.03%
-4.69
Change In Accrued Expense
-0.04
-75.00%
-0.02
-101.33%
1.80
+181.23%
-2.22
Change In Payable
0.14
+113.33%
-1.06
+15.81%
-1.26
+73.03%
-4.69
Change In Account Payable
0.14
+113.33%
-1.06
-4740.91%
-0.02
+97.10%
-0.76
Change In Other Working Capital
-0.12
-120.21%
0.57
-20.17%
0.72
-65.08%
2.06
Investing Cash Flow
8.03
-24.17%
10.58
+9.14%
9.70
-17.69%
11.78
Cash Flow From Continuing Investing Activities
8.03
-24.17%
10.58
+9.14%
9.70
-17.69%
11.78
Net PPE Purchase And Sale
-1.62
-400.93%
-0.32
-23.28%
-0.26
+6.43%
-0.28
Purchase Of PPE
-1.62
-400.93%
-0.32
-23.28%
-0.26
+6.43%
-0.28
Capital Expenditure
-1.62
-400.93%
-0.32
-23.28%
-0.26
+6.43%
-0.28
Net Investment Purchase And Sale
9.27
-15.00%
10.91
+9.51%
9.96
-17.43%
12.06
Purchase Of Investment
—
—
—
0.00
Sale Of Investment
9.27
-15.00%
10.91
+9.51%
9.96
-17.43%
12.06
Net Other Investing Changes
0.37
—
—
—
Financing Cash Flow
9.53
+7.83%
8.84
+10.18%
8.02
+6.99%
7.50
Cash Flow From Continuing Financing Activities
9.53
+7.83%
8.84
+10.18%
8.02
+6.99%
7.50
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
9.58
+10427.47%
0.09
-98.87%
8.02
0.00
Proceeds From Stock Option Exercised
—
—
—
0.00
Net Other Financing Charges
-0.05
-100.54%
8.75
—
7.50
Changes In Cash
-0.65
-146.44%
1.40
+127.34%
-5.13
+70.18%
-17.22
Effect Of Exchange Rate Changes
0.18
+1509.09%
0.01
+150.00%
-0.02
+99.31%
-3.21
Beginning Cash Position
7.67
+22.62%
6.26
-45.19%
11.41
-64.15%
31.84
End Cash Position
7.20
-6.19%
7.67
+22.62%
6.26
-45.19%
11.41
Free Cash Flow
-19.83
-8.10%
-18.34
+20.65%
-23.12
+37.14%
-36.78
Change In Interest Payable
—
—
1.85
+185.27%
-2.17
Common Stock Issuance
9.58
+10427.47%
0.09
-98.87%
8.02
0.00
Issuance Of Capital Stock
9.58
+10427.47%
0.09
-98.87%
8.02
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category